|
|
| | Rosmantuzumab Basic information |
| Product Name: | Rosmantuzumab | | Synonyms: | Rosmantuzumab;Research Grade Rosmantuzumab (DHJ51101);Rosmantuzumab (anti-RSPO3);OMP-131R10;Research Grade Rosmantuzumab | | CAS: | 1684393-04-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Rosmantuzumab Structure]() |
| | Rosmantuzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Rosmantuzumab Usage And Synthesis |
| Uses | Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors[1]. | | in vivo | Rosmantuzumab (25 mg/kg; i.p., once a week for 4 weeks) significantly protects the animals from developing liver fibrosis[1].
Rosmantuzumab (25 mg/kg; i.p., once for two weeks, for total 6 weeks) significantly inhibits skin thickness, collagen deposition, and number of α-SMA positive cells in bleomycin-induced lung fibrosis mouse models[1]. | Animal Model: | Male C57B1/6J CCl4 liver fibrosis mouse models[1] | | Dosage: | 25 mg/kg | | Administration: | Intraperitoneal injection; 25 mg/kg, once a week for 4 weeks | | Result: | Significantly decreased collagen I and collagen III mRNAs, and inhibits β-catenin cytoplasmic and nuclear translocation.
|
| | References | [1] Zhang M, et al. Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. PLoS One. 2020 Mar 11;15(3):e0229445. DOI:10.1371/journal.pone.0229445 |
| | Rosmantuzumab Preparation Products And Raw materials |
|